Antiproliferative, antiangiogenic and apoptotic effect of new hybrids of quinazoline-4(3H)-ones and sulfachloropyridazine

Zahran, Sally S.; Ragab, F. M.; El‐Gazzar, Marwa G.; Soliman, Aiten M.; Mahmoud, Walaa R.; Ghorab, Mostafa M.

doi:10.1016/j.ejmech.2022.114912

Cited by 19 publications

(9 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The NCI-USA antitumor assessment 39 , MTT viability 40 , 41 , VEGFR-2 inhibition 42 , 43 , CA I, II, and IX inhibition studies 44–47 , cell cycle analysis and annexin V-FITC apoptosis assay 48 , 49 were all carried out as previously published in the current study. The supplementary data included descriptions of every experimental technique.…”

Section: Methodsmentioning

confidence: 99%

Discovery of sulfonamide-tethered isatin derivatives as novel anticancer agents and VEGFR-2 inhibitors

Shaldam

Almahli

Angeli

et al. 2023

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

In this work, new isatin-based sulphonamides ( 6a-i , 11a-c , 12a-c ) were designed and synthesised as potential dual VEGFR-2 and carbonic anhydrase inhibitors with anticancer activities. Firstly, all target isatins were examined for in vitro antitumor action on NCI-USA panel (58 tumour cell lines). Then, the most potent derivatives were examined for the potential CA inhibitory action towards the physiologically relevant hCA isoforms I, II, and tumour-linked h CA IX isoform, in addition, the VEGFR-2 inhibitory activity was evaluated. The target sulphonamides failed to inhibit the CA isoforms that could be attributable to the steric effect of the neighbouring methoxy group, whereas they displayed potent VEGFR-2 inhibitory effect. Following that, isatins 11b and 12b were tested for their influence on the cell cycle disturbance, and towards the apoptotic potential. Finally, detailed molecular modelling analyses, including docking and molecular dynamics, were carried out to assess the binding mode and stability of target isatins.

show abstract

Section: Methodsmentioning

confidence: 99%

Discovery of sulfonamide-tethered isatin derivatives as novel anticancer agents and VEGFR-2 inhibitors

Shaldam

Almahli

Angeli

et al. 2023

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

show abstract

“…In their study, Zahran et al [ 46 ] documented the development and creation of innovative sulfachloropyridazine-bearing quinazoline-4(3 H )-one derivatives. The cytotoxic activity of all the produced compounds was evaluated in vitro at a dose of 10 μM against a panel of 60 human cancer cell lines.…”

Section: Quinazolines As Protein Kinases Inhibitorsmentioning

confidence: 99%

Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021–Present)

Abdel-Mohsen,

Anwar,

Ahmed

et al. 2024

Molecules

View full text Add to dashboard Cite

Cancer is a complicated, multifaceted disease that can impact any organ in the body. Various chemotherapeutic agents have a low selectivity and are very toxic when used alone or in combination with others. Resistance is one of the most important hurdles that develop due to the use of many anticancer therapeutics. As a result, treating cancer requires a target-specific palliative care strategy. Remarkable scientific discoveries have shed light on several of the molecular mechanisms underlying cancer, resulting in the development of various targeted anticancer agents. One of the most important heterocyclic motifs is quinazoline, which has a wide range of biological uses and chemical reactivities. Newer, more sophisticated medications with quinazoline structures have been found in the last few years, and great strides have been made in creating effective protocols for building these pharmacologically active scaffolds. A new class of chemotherapeutic agents known as quinazoline-based derivatives possessing anticancer properties consists of several well-known compounds that block different protein kinases and other molecular targets. This review highlights recent updates (2021–2024) on various quinazoline-based derivatives acting against different protein kinases as anticancer chemotherapeutics. It also provides guidance for the design and synthesis of novel quinazoline analogues that could serve as lead compounds.

show abstract

“…For the synthesis of the target derivatives 17-37, we used as starting material 2methoxybezoic acid (1) or 3-methoxy-2-naphthoic acid (2), which were converted to the Beyond their role as kinase inhibitors, quinazolinones possess a rich array of capabilities that extend their utility in oncology. They have the potential to induce apoptosis in cancer cells, a process that triggers programmed cell death and is vital for slowing tumor growth [17,18]. Compounds I and II (Figure 1) are examples of known quinazoline analogs that inhibit tubulin polymerization.…”

Section: Chemistrymentioning

confidence: 99%

Synthesis and Biological Evaluation of 2-Substituted Quinazolin-4(3H)-Ones with Antiproliferative Activities

Karelou,

Kampasis,

Kalampaliki

et al. 2023

Molecules

View full text Add to dashboard Cite

Sixteen new 2-substituted quinazolines were synthesized using a straightforward methodology starting from 2-methoxybezoic acid or 3-methoxy-2-naphthoic acid. The anti-proliferative activity of the target compounds was evaluated against nine cancer cell lines. Additionally, all the compounds were screened for their potency and selectivity against a panel of 109 kinases and four bromodomains, using Differential Scanning Fluorimetry (DSF). Compound 17 bearing a 2-methoxyphenyl substitution along with a basic side chain displayed a remarkable profile against the majority of the tested cell lines.

show abstract

Antiproliferative, antiangiogenic and apoptotic effect of new hybrids of quinazoline-4(3H)-ones and sulfachloropyridazine

Cited by 19 publications

References 63 publications

Discovery of sulfonamide-tethered isatin derivatives as novel anticancer agents and VEGFR-2 inhibitors

Discovery of sulfonamide-tethered isatin derivatives as novel anticancer agents and VEGFR-2 inhibitors

Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021–Present)

Synthesis and Biological Evaluation of 2-Substituted Quinazolin-4(3H)-Ones with Antiproliferative Activities

Contact Info

Product

Resources

About